STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION 
For procedures finalised after 1 September 2004 please refer to module 8B 
• 
• 
• 
• 
• 
• 
• 
• 
• 
On 12 November 1996, SmithKline Beecham plc submitted to the EMEA an application for a 
Type II variation in accordance with Article 6 of Commission Regulation (EC) No. 542/95 of 
10  March  1995.  The  scope  of  the  variation  was  related  to  the  introduction  of  an  additional 
package size of 1 vial of 5 ml in a cardboard carton. The CPMP during their meeting on 16-18 
December  1996  issued  a  positive  Opinion  for  this  Type  II  variation.  The  CPMP  Opinion  was 
forwarded, in all official languages of the European Union, to the European Commission, which 
adopted the corresponding Decision on 15 April 1997. This variation required amendments to 
relevant sections of the previous Commission Decision and the EPAR.  
On  13  August  1997,  the  Marketing  Authorisation  Holder  submitted  a  Type  I  variation  in 
accordance with Commission Regulation  (EC) No. 542/95. This variation related to the batch 
size of the finished product. On 18 September 1997, the EMEA approved this variation, which 
did not require an amendment to the Commission Decision. 
Following  fulfilment  by  the  Marketing  Authorisation  Holder  of  pharmaceutical  follow-up 
measures,  as  agreed  by  the  CPMP  during  their  meeting  on  22-25  September  1997,  relevant 
changes to section III.2 of the EPAR have been made. 
On  16  October  1998  the  Marketing  Authorisation  Holder  submitted  to  the  EMEA  an 
applications for a Type I variation in accordance with Commission Regulation (EC) No. 542/95 
of 10 March 1995, as amended. The scope of the variation was to extend the shelf life. On 20 
November 1998, the EMEA approved the variation. The variation required amendments to the 
Annex  I  (Summary  of  Product  Characteristics)  of  the  Commission  Decision.  The  European 
Commission amended the Decision on 27 January 1999. 
On  26  October  1998,  the  Marketing  Authorisation  Holder  submitted  a  Type  I  variation  in 
accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended. This 
variation related to a change in specifications of the active substance. On 27 November 1998, 
the  EMEA  approved  this  variation,  which  did  not  require  an  amendment  to  the  Commission 
Decision. 
On  9  November  1998,  the  Marketing  Authorisation  Holder  submitted  to  the  EMEA  an 
application for a Type II variation relating to section 4.8 Undesirable effects as well as for the 
amendment  of  details  in  accordance  with  the  updated  EMEA/QRD  template  for  product 
information.  The  Package  Leaflet  was  amended  in  line  with  the  SPC.  The  CPMP,  during  its 
December  plenary  meeting,  considered  the  changes  acceptable,  and  adopted  on  17  December 
1998  a favourable  opinion on the Type II  variation.  The  corresponding Commission  Decision 
was issued on 26 April 1999. 
In accordance with Article 10(3) of Council Directive 92/27 EEC of 31 March 1992, the EMEA 
issued  on  12  April  1999  a  Notification  for  amendments  of  the  addresses  of  the  local 
representatives  included  in  the  package  leaflet  as  applied  by  the  Marketing  Authorisation 
Holder. The Commission amended the Commission Decision on 1 July 1999. 
On  9  April  1999,  the  Marketing  Authorisation  Holder  submitted  two  Types  I  variations  in 
accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended. One 
of  these  variations  related  to  a  change  in  manufacture  of  the  medicinal  product  and  the  other 
related to a change in the specifications of the medicinal product. On 7 May 1999, the EMEA 
approved  the  two  variations,  none  of  which  required  an  amendment  to  the  Commission 
Decision. 
On 9 July 1999, the Marketing Authorisation Holder submitted to the EMEA an application for 
a Type II variation relating to an additional presentation of an already authorised strength. The 
presentations applied for are a 1 mg vial in packs of 1 vial and 5 vials. The CPMP, during its 
October  plenary  meeting,  considered  the  presentation  acceptable,  and  adopted  on  21  October 
1/3 
 EMEA 2005 
 
 
 
 
 
 
 
 
 
• 
• 
• 
• 
• 
1999 a favourable opinion on the Type II variation. The variation required amendments to the 
Annex I (Summary of Product Characteristics) and Annex III (Labelling and Package Leaflet) 
of  the  Commission  Decision.  The  European  Commission  amended  the  Decision  on  16  March 
2000. 
On  1  October  1999,  the  Marketing  Authorisation  Holder  submitted  one  Type  I  variation  in 
accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended. This 
variation related to a change in the name and/or address of the Marketing Authorisation Holder. 
On 19 October 1999, the EMEA approved the variation, which required amendments to annexes 
I, IIIA and IIIB of the Commission Decision. The European Commission amended the Decision 
on 22 February 2000. 
In accordance with Article 10(3) of Council Directive 92/27 EEC of 31 March 1992, the EMEA 
issued  on  19  October  1999  a  Notification  for  amendments  of  the  addresses  of  the  local 
representatives  included  in  the  package  leaflet  as  applied  by  the  Marketing  Authorisation 
Holder. The Commission amended the Commission Decision on 22 February 2000. 
On 20 December 1999, the Marketing Authorisation Holder submitted one Type I variation in 
accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended. This 
variation  related  to  a  change  in  in-process  controls  applied  during  the  manufacturing  of  the 
product.  On  20  January  2000,  the  EMEA  approved  the  variation,  which  did  not  require  an 
amendment to the Commission Decision. 
On  17  April  2000,  the  Marketing  Authorisation  Holder  submitted  one  Type  I  variation  in 
accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended. This 
variation  related  to  a  change  in  in-process  controls  applied  during  the  manufacturing  of  the 
product. On 10 May 2000 EMEA approved the variation, which did not require an amendment 
to the Commission Decision. 
In accordance with Article 10(3) of Council Directive 92/27 EEC of 31 March 1992, the EMEA 
issued on the 7 July 2000 and 3 August 2000 a Notification for amendments of the addresses of 
the  local  representatives  included  in  the  package  leaflet  as  applied  by  the  Marketing 
Authorisation  Holder.  The  Commission  amended  the  Commission  Decision  for  both 
notifications on the 25 September 2000. 
2/3 
 EMEA 2005 
 
 
 
 
 
 
 
 
Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below: 
Scope 
Application 
number 
Type of 
modification1 
Update of the Summary of Product Characteristics on the risk and 
benefits of prolonged use 
Update of the Summay of Product Characteristics Section 4.8 
following the assessment of the 6th PSUR 
Change in test procedure of active substance 
Changes to comply with supplements to pharmacopoeias 
5-year renewal of the Marketing Authorisation 
Update of the Summay of Product Characteristics Sections 4.5, 4.8 
Change in the name of the marketing authorisation holder 
Change in the address of the marketing authorisation holder 
Minor change in labelling or package leaflet not connected with 
the SPC (Art. 61.3 Notification) 
Minor change in labelling or package leaflet not connected with 
the SPC (Art. 61.3 Notification) 
Change in the batch size of finished product 
Change(s) to container 
Change(s) to the manufacturing process for the active substance 
Minor change in labelling or package leaflet not connected with 
the SPC (Art. 61.3 Notification) 
Minor change in labelling or package leaflet not connected with 
the SPC (Art. 61.3 Notification) 
II/17 
II/18 
I/19 
I/20 
R/21 
II/22 
I/23 
I/24 
N/25 
N/27 
I/29 
II/30 
II/31 
N/32 
N/33 
II 
II 
I 
I 
R 
II 
I 
I 
N 
N 
I 
II 
II 
N 
N 
Notification/ 
Opinion issued 
on2 
14.12.00 
Commission 
Decision 
Issued/amen
ded on 
20.03.01 
07.06.01 
22.06.01 
25.04.02 
24.05.02 
24.05.02 
08.11.02 
13.09.01 
05.07.01 
05.07.01 
04.02.02 
30.07.02 
30.07.02 
30.07.02 
11.12.02 
17.01.03 
06.02.03 
12.06.03 
24.07.03 
25.09.03 
27.06.03 
15.06.04 
17.06.03 
28.07.03 
26.09.03 
18.07.03 
- 
1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers to a 
minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a minor 
variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an Annex II 
application. 
T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 
of 7 November 1996.  
N refers to a notification in accordance with Article 61(3) of Directive 2001/83/EC. 
2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification 
date. The Commission Decision will be amended accordingly. 
3/3 
 EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                            
 
